By selectively inhibiting NNMT , 5-Amino-1MQ can reduce the methylation of nicotinamide, leading to increased intracellular NAD availability and enhanced metabolic activity
A reasonable time for an eval may be 30 days / nights
Biomarkers studied in more than one country included those related to the androgen receptor (AR), ribonuclease L (RNASEL), glutathione S-transferase enzymes T1, M1, and P1 (GSTM1, GSTT1, and GSTP1), cytochrome P450, 3-oxo-5-steroid 4-dehydrogenase 2 (SRD5A2), vitamin D receptor (VDR), and the non-coding region at 8q24.21
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
This targeted mechanism minimizes the risk of off-target effects and supports the compounds favorable safety profile
